<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-11 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-11</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-11</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-8ec4976eab8d70e9dc518b3e5ddd43ba2321251a</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/8ec4976eab8d70e9dc518b3e5ddd43ba2321251a" target="_blank">Melanoma: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner</a></p>
                <p><strong>Paper Venue:</strong> Journal of the Advanced Practitioner in Oncology</p>
                <p><strong>Paper TL;DR:</strong> Data is reviewed on adjuvant therapy in stage IIB or IIC melanoma and omitting lymph node dissection and adjuant therapy in patients with resectable stage III melanoma with major pathologic response.</p>
                <p><strong>Paper Abstract:</strong> Suzanne McGettigan, MSN, CRNP, AOCNÂ®, of Abramson Cancer Center of the Hospital of the University of Pennsylvania, reviews data on adjuvant therapy in stage IIB or IIC melanoma and omitting lymph node dissection and adjuvant therapy in patients with resectable stage III melanoma with major pathologic response.</p>
                <p><strong>Cost:</strong> 0.002</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <p class="empty-note">No extracted data.</p>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <p class="empty-note">No potentially relevant new papers extracted.</p>
        </div>

        </div>

    </div>
</body>
</html>